A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Trial Profile

A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ENDEAVOR
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2017 Long-term data from this trial published in the Media Release.
    • 30 Aug 2017 According to an Amgen media release, the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for the treatmend of Relapsed or Refractory Multiple Myeloma, to include the overall survival data of carfilzomib from this trial. The US FDA has granted a PDUFA date of April 30, 2018 for the review.
    • 23 Aug 2017 Results of second interim analysis (as of 3 Jan 2017) published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top